A Wrinkle in Common Rule Time

January 18, 2018 Alerts and Newsletters

January 18, 2018 - In an 11th hour—but nonetheless anticipated—move, the sixteen federal departments and agencies responsible for the Common Rule Final Rule that was slated to become effective tomorrow, January 19, 2018 ("Revised Common Rule"), have issued an Interim Final Rule ("IFR ") delaying the effective date and the general compliance date of the Revised Common Rule for six months, until July 19, 2018. The IFR does not alter the compliance date for the Revised Common Rule's provision on cooperative research (including its single IRB mandate); that date remains January 20, 2020.

The announcement provides a respite to those in the regulated community who have been working towards bringing their policies and procedures into compliance by January 19, 2018, despite the lack of any written guidance from the Office for Human Research Protections or others in the federal government regarding aspects of the Revised Common Rule that are ambiguous or otherwise challenging to implement.

The IFR acknowledges that "regulated entities need additional time for implementation and compliance, which would be furthered by the issuance of guidance by the Common Rule agencies" as part of its justification for issuing the delay through the IFR process without the normally required period for public notice-and-comment.

Serving as a "pause" button in what has been a perplexing process for many in the regulated community, the IFR contemplates that the federal departments and agencies will use the delay period to pursue additional rulemaking to extend further the effective date and compliance date for the Revised Common Rule to January 21, 2019.

One puzzling aspect of the IFR is its stated "effective date." Although the government is indicating that the delay outlined in the IFR serves to stay tomorrow's compliance and effective dates for the Revised Common Rule, the IFR states that the IFR itself has an effective date of July 19, 2018, which is the same day the Revised Common Rule would also become effective pursuant to the IFR. Our understanding is that the identification of this date may be driven by the fact that the delay is being issued prior to the Revised Common Rule going into effect, and because the IFR seeks to modify specific language in the "transition" provisions of the as-yet-effective Revised Common Rule at §___101(l) (which explicitly sets forth the effective and compliance dates). However, the express statements in the IFR that it does not take effect until the Revised Common Rule would already have been in effect for six months under the original Final Rule has caused some confusion in the regulated community and among regulatory attorneys. Again, all indications from the government are that the delay is effective immediately notwithstanding the IFR's stated effective date, and that this confusion is simply the result of a regulatory technicality.

Importantly, the regulated community should note that early compliance with the flexible aspects of the Revised Common Rule remains prohibited ahead of July 19. Institutions may elect to implement aspects of the Revised Common Rule that are more stringent than the current regulations (for example, the new elements of informed consent related to secondary uses), but may not take advantage of flexibilities, such as broad consent and the new categories of exempt research, at this time.

We have updated our 2018 Common Rule Implementation Checklist in light of the new effective date and compliance date, and have added some additional reflection on particular regulatory provisions since the checklist was originally circulated. We include this updated Implementation Checklist here for your reference. For more information about the delay or the ACRG's Implementation Checklist, or to discuss your institution's plans for compliance with the 2018 Common Rule, please feel free to contact the member of Verrill Dana's Academic and Clinical Research Group with whom you normally work, or email us at [email protected].

___________________________________________________________________
This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights

Matter

Trademark Litigation: Software

Represented trademark owner in litigation with foreign software company. Successfully defeated motion to dismiss on jurisdictional grounds, which was affirmed on appeal. Also successfully defeated summary judgment motion, which resulted in case settling before...

News

High-Profile Former U.S. Department of Justice Prosecutor, David Lazarus, Joins Verrill’s Health Care and Life Sciences Practice

(November 29, 2021) – Verrill is pleased to welcome David Lazarus to the firm’s Boston office as a Partner in its nationally recognized Health Care & Life Sciences Group. Lazarus is a former Department...

Publication/Podcast

Connecticut Supreme Court Rejects Tough Delaware Standard in Allowing Member Inspections of Manager-Managed LLC Books and Records – Or Does It?

Before allowing the inspection of corporate books and records, Delaware courts require a shareholder seeking information about possible mismanagement to come forward with evidence demonstrating a reasonable basis to suspect mismanagement. [1] In Benjamin...

Matter

Copyright Litigation: Software

Defended equipment manufacturer in copyright dispute involving firmware for digital subscriber line access multiplexers (“DSLAMs”). Case resolved favorably.

Blog

You Are Here: A Mall Directory for Healthcare Transparency Requirements

The old adage “you can’t get where you’re going unless you know where you are” has never seemed more true than when applied to the current mélange of healthcare transparency guidance. Fortunately, a fading...

Event

Boston Bar Association Virtual CLE: The New 2021 Child Support Guidelines in Practice

On Monday, December 6 from 2:00PM to 4:00PM Verrill attorney David Friedman will be speaking at the Boston Bar Association's Virtual CLE: The New 2021 Child Support Guidelines in Practice. David and the other...

News

The Boston Globe on Federal Prosecutor Joining Verrill

Event

Medicare's Future: Improving Health Equity and Implications for Employers

On Wednesday, December 15th at 2 pm join the National Academy of Social Insurance , Verrill , the New England Council , and the Massachusetts Hospital Association for a virtual discussion on the future...

Publication/Podcast

Breaking: OSHA Releases Emergency Temporary Standard for Employers with 100 or More Employees

Blog

California’s AB 488: You Can Check Out Any Time You Like But You Can Never Leave

The State of California is getting a firm grip on regulating charitable sales promotions with its new law AB 488 which passed in October 2021 and will become effective January 1, 2023 (in order...

Contact Verrill at (855) 307 0700